T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

  • Tran E
  • Robbins P
  • Lu Y
  • et al.
1.0kCitations
Citations of this article
1.4kReaders
Mendeley users who have this article in their library.

Abstract

Copyright © 2016 Massachusetts Medical Society. All rights reserved. We identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer. We observed objective regression of all seven lung metastases after the infusion of approximately 1.11×1011 HLA-C∗08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C∗08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C∗08:02.

Cite

CITATION STYLE

APA

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., … Rosenberg, S. A. (2016). T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. New England Journal of Medicine, 375(23), 2255–2262. https://doi.org/10.1056/nejmoa1609279

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free